CD19 is a protein on B cells from the start until they mature. It’s always there, even on cancerous B cells. This makes CD19 ...

Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced the upcoming presentation of preclinical data for ...

ImmunityBio has announced the commencement of a Phase I clinical trial evaluating its CD19 targeted high-affinity natural ...

CD19, a B-cell surface protein, is expressed across B-cell development and it is expressed on almost all B-cell malignancies, such as ALL, chronic lymphocytic leukemia (CLL) and several non ...

Sana Biotechnology has become the latest cell therapy biotech to shift resources from cancer to autoimmune diseases as part of a ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

Santa Monica, California Thursday, November 7, 2024, 10:00 Hrs [IST] ...

ImmunityBio has around $130.1 million in cash, enough to fund operations for at least the next 12 months. Read why I'm very ...

Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 ...

The anti-CD19 monoclonal antibody was effective in a combined population with acetylcholine receptor autoantibody-positive (AChR+) or muscle-specific kinase autoantibody-positive (MuSK+ ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious ...